Glucose-6-phosphate dehydrogenase deficiency among neonates with jaundice in Africa; systematic review and meta-analysis

Kassahun, Woldeteklehaymanot; Tunta, Abayneh; Abera, Atitegeb; Shiferaw, Mulu

doi:10.1016/j.heliyon.2023.e18437

Cited by 4 publications

(2 citation statements)

References 51 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, a recent study by Kassahun et al (17) , reported that with significant heterogeneity (I2 = 100%), G6PD deficiency was common in 24.60% of African newborns with jaundice (95% CI:12.47-36.74). G6PD insufficiency was highest in Nigerian newborns with jaundice (49.67%) and lowest in South African neonates (3.14%).…”

Section: Discussionmentioning

confidence: 99%

Preliminary Results of Neonatal Screening of 19 Genetic and Metabolic Disorders in Qalyubia Governorate

2024

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Tandem mass spectrometry (MS/MS) expanded neonatal screening for inborn errors of metabolisms (IEMs) and it is an effective method for early diagnosis and presymptomatic therapy to avoid serious long-term consequences and mortality. Objective: To detect the prevalence of the preventable 19 IEM screened among neonates in NICUs of our community and identify types of IEM most commonly found in Qalyubia Governorate. Screening obstacles were also addressed to be resolved appropriately with provision of purposeful family counseling. Methods: This cross-sectional study was performed on neonates admitted to NICU of Benha Children Hospital in Qalyubia Governorate for early detection of 19 neonatal genetic diseases and early treatment of positive ones for duration of one year from June 2022 to June 2023. This study included 700 neonates. All neonates were subjected to detailed history taking, detailed examination and assessment of 19 genetic and metabolic disorders. Results: Regarding the screening test for 19 genetic and metabolic disorders of the studied group, 19 (2.71%) patients were true positive, 51 (7.29%) patients were false positive, and 630 (90%) patients were negative. Congenital adrenal hyperplasia was confirmed in 1 (0.14%) patient, G6PD enzyme deficiency was confirmed in 16 (2.29%), and urea cycle defect was confirmed in 1 (0.14%) patient and elevated TSH and confirmatory free T4 recommended was found in 1 (0.14%) patient. Regarding the outcome of the positive cases, 18 (94.74%) patients survived, and 1 (5.26%) patient did not survive (urea cycle defect). The diagnostic accuracy of the screening test was 92.7%, with 100% sensitivity, 92.5% specificity, 27.1% PPV and 100% NPV. This test was proven to be an effective and good negative test. Conclusion: This test was proven to be an effective and good negative test. Even before they showed symptoms, infants who were tested positive for illnesses were treated promptly. Thus, it might lower health care expenses and prevent or reverse serious disability.

show abstract

Section: Discussionmentioning

confidence: 99%

Preliminary Results of Neonatal Screening of 19 Genetic and Metabolic Disorders in Qalyubia Governorate

2024

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

show abstract

“…Glucose-6-phosphate dehydrogenase (G6PD) is an enzyme found in the cytoplasm of all cells. The oxidation of glucose-6-phosphate to 6phosphogluconate is catalysed by glucose-6phosphate dehydrogenase (G6PD) in the pentose phosphate pathway, which is also known as the hexose monophosphate shunt (Kassahun et al, 2023;Albagshi et al, 2020). In order to achieve this goal, nicotinamide adenine dinucleotide phosphate, often known as NADPH, is synthesised from NADP.…”

Section: Introductionmentioning

confidence: 99%

Prevalence Of Glucose-6-Phosphate Dehydrogenase Deficiency in People Living in Katsina Metropolis

Osibemhe,

Hauwa’u

2023

IJSGS

View full text Add to dashboard Cite

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the most prevalent human enzyme defects observed in malaria endemic areas. The study included 212 participants, with 142 (67%) male and 70 (33%) female, aged between14 to 59 with a mean age of 24.20±9.35 years. The study was granted ethical approval by the Katsina State Ministry of Health. Each subject gave his/her written informed permission after counseling. G6PD deficiency, malaria parasite, reduced glutathione (GSH), glutathione peroxidase (GPx), packed cell volume (PCV) and hemoglobin (Hb) were assayed using standard procedures. Among the 212 participants tested in the study, 40 (19%) were found to be G6PD deficient and 172 (81%) participants were normal. Among 212 participants tested, 75 (35.4%) were infected with malaria parasite out of which 13 (17.3%) were G6PD deficient and 62 (82.7%) were normal. Among the 40 G6PD deficient subjects, 33 (82.5%) were male while 7 (17.5%) were females. GSH concentration was lowered significantly in G6PD-deficient subjects compared to the normal subjects. GPx, Hb and PCV showed no significant difference (p>0.05) in the deficient subjects compared to the normal subjects. The results of this study suggest that G6PD deficiency is quite common with a prevalence of 19% in the population of Katsina metropolis. The data also shows that males are more likely to be affected by G6PD deficiency than females.

show abstract

The Impact of the G6PD Gene Mutations in Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals: A Multicenter Observational Study

Smirne,

Crobu,

Gerevini

et al. 2024

Genes

View full text Add to dashboard Cite

Following the advent of direct-acting antivirals (DAAs), the treatment of hepatitis C virus (HCV) infection is now rarely challenging. However, data are still limited concerning DAA use in patients affected by glucose-6-phosphate dehydrogenase deficiency (G6PDd). Based on these considerations, the goal of this study was to evaluate the effectiveness and safety of DAAs in this subpopulation. A retrospective multicenter observational study (2015–2023) was conducted on all 2754 consecutive HCV-positive patients treated with first- and second-generation all-oral DAAs, and with a G6PDd diagnosis confirmed by quantitative testing (n = 38). At the treating clinician’s discretion, an enhanced clinical and laboratory follow-up was performed, generally on a monthly basis both during treatment and up to six months after the end of it. Concerning hematochemical parameters, no significant differences were found between any considered time point. In all cases, no treatment-related adverse events were reported, and virologic response rates were as expected without G6PDd. In conclusion, in a large experience which, to the best of our knowledge, is unprecedented in the literature, the treatment of HCV hepatitis with nearly all available DAAs in patients with G6PDd as a comorbidity—a common occurrence in countries such as Italy—proved to be highly effective and safe.

show abstract

Glucose-6-phosphate dehydrogenase deficiency among neonates with jaundice in Africa; systematic review and meta-analysis

Cited by 4 publications

References 51 publications

Preliminary Results of Neonatal Screening of 19 Genetic and Metabolic Disorders in Qalyubia Governorate

Preliminary Results of Neonatal Screening of 19 Genetic and Metabolic Disorders in Qalyubia Governorate

Prevalence Of Glucose-6-Phosphate Dehydrogenase Deficiency in People Living in Katsina Metropolis

The Impact of the G6PD Gene Mutations in Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals: A Multicenter Observational Study

Contact Info

Product

Resources

About